Ensuring sustainable growth
- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
- Individual shareholders
- U.S. investors
- Regulated information in France
Message from the Chairman
The second quarter 2017 was marked by the launch of our Immunology franchise with the approval of Kevzara® in moderate to severe adult rheumatoid arthritis in the United States and the European Union, and Dupixent®, a revolutionary treatment for atopic dermatitis, in the United States. These important achievements demonstrate the robustness of Sanofi's portfolio and remind us of the importance of innovation in meeting patients’ unmet needs...
Interview with the Chief Executive Officer
How would you assess the Second Quarter of 2017?
I’m satisfied with our results in the second quarter and beyond, with the better than expected financial performance in the first half of the year. Once again this quarter, Sanofi Genzyme, Sanofi Pasteur and Emerging Markets contributed strongly to our performance...
Can you tell us more about the performance of Sanofi Genzyme, Sanofi Pasteur and Emerging Markets?
Sanofi Genzyme's Specialty Care franchise was up 13.6%1, with growth in all businesses across both developed and emerging markets...
What about progress in Research & Development?
I would like to highlight the following major developments. Dupilumab entered phase 3 in adolescent atopic dermatitis and pediatric asthma. In oncology, our PD-1 inhibitor...
SECOND QUARTER 2017 RESULTS
Net sales were €8,663M in the second quarter of 2017, an increase of 6.4% on a reported basis and 5.5% at CER, reflecting the change in scope of the Global Business Units Consumer Healthcare (acquisition of Boehringer Ingelheim's Consumer Healthcare business and the disposal of the Animal Health business) and Vaccines (consolidation of Sanofi's vaccine business in Europe). At CER and constant structure (CS), Sanofi's sales growth was 0.6%, a slight increase, despite the accelerated decline of the Diabetes franchise.
- Growth rates are expressed at constant exchange rates (CER). Growth rates in brackets are expressed on a reported basis. For definitions of financial indicators, please consult the press release issued on July 31, 2017
- Earnings per share
- CS: constant structure: adjusted for BI CHC business, termination of SPMSD and others
Kevzara® approved in Europe for adults with moderately to severly active rheumatoid arthritis
At the end of June 2017, the European Commission granted marketing authorization to Kevzara® (sarilumab) in combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately or who are intolerant to one or more disease modifying anti-rheumatic drugs, such as methotrexate...
Dupilumab: new clinical data and regulatory milestones
On July 21, 2017, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the marketing authorization of Dupixent®. It recommends its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy...
On September 28, 2017, the European Commission has granted marketing authorization for Dupixent® (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Cemiplimab receives breakthrough therapy designation for advanced cutaneous squamous cell carcinoma
- Approval in Europe of Insulin Lispro Sanofi®
- Collaboration with Ablynx signed
- Sanofi rated AA by Scope Ratings
Acquisition of Protein Sciences
On August 28, 2017, Sanofi completed the acquisition de Protein Sciences, a U.S. vaccines biotechnology company. This completion follows Federal Trade Commission approval, having met all the conditions required for the closing of the transaction. The acquisition of Protein Sciences will help strengthen our leadership positions in the influenza vaccine market.
Visit to Ambarès production site by the Shareholders Committee
On June 28, 2017, the Individual Shareholders Committee visited Sanofi’s Ambarès production site, near Bordeaux, France. Ambarès is a major manufacturing and packaging facility specialized in two types of production: dry formulas (tablets, coated tablets, capsules) and injectables in the form of ampoules. The site manufactures some of Sanofi’s key products in the areas of cardiovascular disease (Plavix®, Aprovel®), central nervous system (Tranxene®), epilepsy as well as consumer healthcare (Maxilase®, Magné B6®).
Save the date for Salon Actionaria 2017
The Sanofi Investor Relations team will be happy to welcome you at the 20th edition of Actionaria, Europe’s largest exhibition for individual shareholders: on November 23 & 24, 2017 at the Palais des Congrès de Paris, 2 Place de la Porte Maillot, 75017 Paris.
Upcoming shareholder meetings in France
Every year, Sanofi participates in informational meetings organized in France by the F2iC (Fédération des Investisseurs Individuels et des Clubs d'investissement) and the financial publications Le Revenu and Investir / Les Echos.
In the first half of 2017, Sanofi participated in four meetings to present Sanofi’s business and news. We warmly thank all shareholders for their participation in Lille, Nice, Versailles and Bordeaux.
Sanofi will participate in a shareholder meeting in Rouen on December 18, 2017.